Related references
Note: Only part of the references are listed.A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A. Lachowiez et al.
BLOOD CANCER DISCOVERY (2023)
Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Daniel A. Pollyea et al.
CLINICAL CANCER RESEARCH (2022)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)